Azitra Inc（AZTR）のニュースとイベントAZTRAzitra Inc

Azitra Expands Patient Eligibility for ATR04-484 Clinical Trial

Azitra announced amendments to its ongoing Phase 1/2 clinical trial of ATR04-484 that expand patient eligibility to include individuals with rash associated with KRAS and MEK inhibitors. The expanded eligibility also includes patients with neurofibromatosis type 1 with rash associated with MEK inhibitors. The amendments also shorten the required washout periods for antibiotics and steroids. Together, these changes broaden the potential treatment opportunities for ATR-04 beyond its initial focus on epidermal growth factor receptor inhibitor-associated skin rash, while expanding the pool of eligible patients to facilitate recruitment. The Phase 1/2 study is evaluating the safety, tolerability, bioavailability, pharmacodynamics, and preliminary efficacy of topical ATR04-484. KRAS inhibitors and MEK inhibitors are precision therapeutics used to treat various cancers, including NSCLC, melanoma, colorectal cancer, and ovarian cancer.

Azitra COO to Present ATR-COSF Progress at BIO-Europe

Azitra COO Travis Whitfill will present progress for its cosmetic ATR-COSF program targeting the appearance of fine lines and wrinkles at the BIO-Europe conference in Cologne on November 10th. The ATR-COSF program uses the supernatant from a strain of S. epidermidis engineered to secrete a functional unit of the human filaggrin protein and is formulated in a hydrogel. The cosmetic product candidate was evaluated in two different models of ex vivo cosmetic surgery skin, which was maintained in serum free, nutrient-rich media. Ex vivo data in two models of recent cosmetic surgery explants showed visible improvements in fine lines, wrinkles and elasticity after a single dose with the ATR-COSF cosmetic product candidate. Continued improvement was seen in up to 48 hours. Initial results in a first-in-human study with ATR-COSF are anticipated by year end.

Azitra Completes Cohort 1 of ATR04-484 Clinical Trial

Azitra announced the completion of Cohort 1 in its Phase 1/2 clinical trial evaluating ATR04-484 as a potential treatment for EGFR inhibitor-associated skin rash. Following its review of available safety data from patients enrolled in Cohort 1, the study's safety review committee recommended that the trial may proceed to Cohort 2, enabling Azitra to begin enrollment and dosing in the second cohort.